San Diego, CALIFORNIA3 Active Studies

Interstitial Lung Disease Clinical Trials in San Diego, CALIFORNIA

Find 3 actively recruiting interstitial lung disease clinical trials in San Diego, CALIFORNIA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
1,068
Enrolling

Recruiting Interstitial Lung Disease Studies in San Diego

About Interstitial Lung Disease Clinical Trials in San Diego

Interstitial lung disease is a group of disorders characterized by progressive scarring of lung tissue, leading to breathlessness and reduced oxygen exchange. Causes include autoimmune diseases, environmental exposures, and unknown factors. Treatment includes antifibrotic medications and immunosuppressants.

There are currently 3 interstitial lung disease clinical trials recruiting participants in San Diego, CALIFORNIA. These studies are seeking a combined 1,068 participants. Research is being sponsored by United Therapeutics, Vicore Pharma AB, AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.

Interstitial Lung Disease Clinical Trials in San Diego — FAQ

Are there interstitial lung disease clinical trials in San Diego?

Yes, there are 3 interstitial lung disease clinical trials currently recruiting in San Diego, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Diego?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Diego research site will contact you about next steps.

Are clinical trials in San Diego free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Diego studies also compensate for your time and travel.

What interstitial lung disease treatments are being tested?

The 3 active trials in San Diego are testing new therapies including novel drugs, biologics, and treatment approaches for interstitial lung disease.

Data updated March 2, 2026 from ClinicalTrials.gov